Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 6;8(24):22132-22137.
doi: 10.1021/acsomega.3c02358. eCollection 2023 Jun 20.

Swim in the Chiral Pool: MDMA and MDA Enantiomers from Alanine-Derived Precursors

Alexander M Sherwood  1 , Elise K Burkhartzmeyer  1 , Samuel E Williamson  1 , Michael T Faley  1
Affiliations

Swim in the Chiral Pool: MDMA and MDA Enantiomers from Alanine-Derived Precursors

Alexander M Sherwood et al. ACS Omega. .

Abstract

A divergent two-step process has provided access to optically pure enantiomers of MDMA and MDA, clinically relevant phenylisopropylamine entactogens. Target compounds were synthesized from commercially available alanine-derived aziridines. Critical process parameters were identified, and the reactions were optimized to avoid chromatographic purifications toward gram-scale isolations, providing (R)-(-)-MDMA, (S)-(+)-MDMA, (R)-(-)-MDA, and (S)-(+)-MDA each in greater than 98% purity by UPLC, >99% enantiomeric excess, and net yields between 50 and 60% for the complete process.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structures of MDMA (1), MDA (2), and corresponding stereoisomers.
Scheme 1
Scheme 1. (A) Regiospecific Ring Opening of Tosyl-Protected Aziridine 4 As Described by Huot et al. and Nenajdenko et al.; (B) Chiral Pool Synthesis of Requisite boc-Aziridine R-6 from d-Alanine; and (C) Optimized Two-Step Divergent Route to 1 and 2 Employing boc-Aziridine 6 (This Work)
Figure 2
Figure 2
Overlaid chromatograms for isolated 7 (red), quenched Grignard solution 3 (blue), and labeled impurity peaks with putative structures 8 and 9 derived from 3.
Scheme 2
Scheme 2. Byproduct Formation and Fate with Extended Reaction Times in the Formation of 7
Figure 3
Figure 3
Monitored intermediate in lithium aluminum hydride reduction of 7.
See this image and copyright information in PMC

References

    1. Shulgin A. T.History of MDMA. In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Topics in the Neurosciences; Peroutka S. J., Ed.; Kluwer Academic Publishers: Boston, MA, 1990; vol 9, pp 1–20, 10.1007/978-1-4613-1485-1_1. - DOI
    1. Freudenmann R. W.; Öxler F.; Bernschneider-Reif S. The Origin of MDMA (Ecstasy) Revisited: The True Story Reconstructed from the Original Documents. Addiction 2006, 101, 1241–1245. 10.1111/j.1360-0443.2006.01511.x. - DOI - PubMed
    1. Sherwood A. M.; Prisinzano T. E. Novel Psychotherapeutics–a Cautiously Optimistic Focus on Hallucinogens. Expert Rev. Clin. Pharmacol. 2018, 11, 1–3. 10.1080/17512433.2018.1415755. - DOI - PMC - PubMed
    1. Sessa B.; Higbed L.; Nutt D. A Review of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Front. Psychiatry 2019, 10, 138. 10.3389/fpsyt.2019.00138. - DOI - PMC - PubMed
    1. Mitchell J. M.; Bogenschutz M.; Lilienstein A.; Harrison C.; Kleiman S.; Parker-Guilbert K.; Otalora G. M.; Garas W.; Paleos C.; Gorman I.; Nicholas C.; Mithoefer M.; Carlin S.; Poulter B.; Mithoefer A.; Quevedo S.; Wells G.; Klaire S. S.; van der Kolk B.; Tzarfaty K.; Amiaz R.; Worthy R.; Shannon S.; Woolley J. D.; Marta C.; Gelfand Y.; Hapke E.; Amar S.; Wallach Y.; Brown R.; Hamilton S.; Wang J. B.; Coker A.; Matthews R.; De Boer A.; Yazar-Klosinski B.; Emerson A.; Doblin R. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Nat. Med. 2021, 27, 1025–1033. 10.1038/s41591-021-01336-3. - DOI - PMC - PubMed